Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma

Inclusion Criteria: * Newly diagnosed and histologically confirmed glioblastoma * Recursive partitioning analysis (RPA) class III or IV * Age \> or = 18 years and \< 75 years of age * Life expectancy \> or = 6 months * Patient must have at least 1 formalin fixed paraffin embedded tumor tissue block representative of glioblastoma available for pathology central review and biomarker exploration * Adequate hematologic (absolute neutrophil count (ANC) \> or = 1.5 x 109/L, platelet count \> or = 100 x 109/L, hemoglobin \> or = 10 g/dL ), renal (creatinine \> or = 1.25 x ULN ), and hepatic function (total bilirubin \< or = 1.5 x ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< or = 2.5 x ULN) * Patients who were receiving corticosteroids had to receive a stable or decreasing dose for at least 14 days before enrollment * Patients must be able to swallow and retain oral medication * Women must have a negative serum pregnancy test less than 7 days prior to the first dose of study drug * Both men and women of reproductive potential agree to use approved contraception during the study and for 6 months after discontinuation of study treatment. * Willing and able to comply with the protocol as judged by the investigator * Patients must provide written consent Exclusion Criteria: * Any prior chemotherapy (including carmustine-containing wafers) or immunotherapy (including vaccine therapy ) * Any prior radiotherapy to the brain * Any contraindication to temozolomide listed in the local label * Have had, in the judgment of the investigator, a major bowel resection that would alter oral drug absorption * Have a diagnosis of inflammatory bowel disease (Crohn's disease or ulcerative colitis) * Have previously completed or withdrawn from this study or any other study investigating LY2228820 * Are receiving, in the judgment of the investigator, concurrent administration of immunosuppressive therapy * Diarrhea of any cause CTCAE \> or = grade 2 * Current or recent (within 30 days of enrollment) treatment with another investigational drug or participation in another investigational study * History of other malignancy within 5 years prior enrollment except for basal cell carcinoma of the skin or carcinoma in situ of the cervix * Pregnant or nursing (lactating) woman, or fertile women unwilling or unable to use effective means of contraception * Psychiatric illness / social situations that would compromise patient safety or limit compliance with study requirements including maintenance of a compliance / pill diary